长春高新：赛增医疗签订GenSci098注射液项目独家许可协议

Core Viewpoint - Changchun High-tech (000661) announced a licensing agreement with Yarrow Bioscience, Inc. for the GenSci098 injection project, which is expected to generate significant financial benefits for the company [1] Group 1: Financial Aspects - The agreement includes an initial payment of $120 million and potential milestone payments related to development, regulatory, and commercialization efforts [1] - Changchun High-tech could receive up to $1.365 billion in milestone payments related to the exclusive license [1] - After the product launch, the company will be entitled to receive over 10% of net sales as a royalty [1]